NKp46 antibody and its use

By developing antibodies or antigen-binding fragments that can bind human and monkey NKp46, the problem of lack of such antibodies in the prior art is solved, and the activation of NK cells and potential tumor therapeutic effects are achieved.

CN116284396BActive Publication Date: 2025-03-28HEFEI TG IMMUNOPHARMA CO LTD
4 Cites 0 Cited by

Patent Information

Application Number
CN202211644532.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-20
Publication Date
2025-03-28
Estimated Expiration
2042-12-20

AI Technical Summary

Technical Problem

The lack of antibodies that can bind both human and monkey NKp46 in the prior art limits the safety evaluation of drugs in non-human primates and studies on NK cell activation.

Method used

An antibody or antigen binding fragment is developed that contains a specific CDR amino acid sequence that is able to bind to NKp46, thereby promoting activation of NK cells. The antibody or antigen binding fragment can be used to prepare recombinant proteins, multispecific antibodies, nucleic acid molecules, expression vectors, recombinant cells, pharmaceutical compositions, conjugates and kits.

Benefits of technology

Effective binding of NKp46 is achieved, the activation of NK cells is promoted, and it has potential application to the prevention and treatment of tumors or cancers.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention proposes an antibody or antigen-binding fragment. The antibody or antigen-binding fragment comprises a CDR selected from at least one of the following: heavy chain variable region CDR: SEQ ID NO: 1-3, 7-9 and 13-15 or an amino acid sequence of a conservative modification thereof; light chain variable region CDR: SEQ ID NO: 4-6, 10-12 and 16-18 or an amino acid sequence of a conservative modification thereof. The antibody or antigen-binding fragment according to an embodiment of the present invention can bind to NKp46, promote the activation of NK cells, and can be used to prevent or treat tumors or cancer.
Need to check novelty before this filing date? Find Prior Art